8-K Announcements
6Material company update
Mar 20, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Dec 15, 2025·SEC
Relmada Therapeutics, Inc.(RLMD)Earnings, Financials & Key Ratios
RLMD•NASDAQ
$7.43
$545M mkt cap·Price updated May 7, 2026
AboutRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.Show more
- Revenue$0
- EBITDA-$59M+29.6%
- Net Income-$57M+28.3%
- EPS (Diluted)-1.45+45.3%
- ROE-94.05%+28.9%
- ROIC-77.3%+30.6%
RLMD Key Insights
Relmada Therapeutics, Inc. (RLMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 98 (top 2%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 30.9% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RLMD Price & Volume
Relmada Therapeutics, Inc. (RLMD) stock price & volume — 10-year historical chart
Loading chart...
RLMD Growth Metrics
Relmada Therapeutics, Inc. (RLMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM28.25%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM44.53%
Return on Capital
10 Years-142.33%
5 Years-99.85%
3 Years-108.89%
Last Year-96.02%
RLMD Recent Earnings
Relmada Therapeutics, Inc. (RLMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
Mar 19, 2026EPS
$0.27
Est $0.14
-92.9%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$0.30
Est $0.04
-650.0%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.30
Est $0.25
-20.0%
Revenue
—
Q2 2025
May 12, 2025EPS
$0.58
Est $0.31
-87.1%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 19, 2026 | $0.27vs $0.14-92.9% | — |
| Q4 2025 | Nov 13, 2025 | $0.30vs $0.04-650.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.30vs $0.25-20.0% | — |
| Q2 2025 | May 12, 2025 | $0.58vs $0.31-87.1% | — |
Based on last 12 quarters of dataView full earnings history →
RLMD Peer Comparison
Relmada Therapeutics, Inc. (RLMD) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AXSM | 11.33B | 220.10 | -59.81 | 65.55% | -26.59% | -260.01% | 2.73 | |
 ALTO | 350.91M | 4.54 | 28.38 | -4.9% | 1.45% | 6% | 0.40 | |
 INVA | 1.93B | 22.80 | 6.91 | 18.52% | 118.91% | 46.47% | 0.23 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INTR | 2.95B | 6.70 | 11.44 | 50.54% | 13.66% | 2.85 | ||
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 NRXP | 84.71M | 3.06 | -2.28 | -157.28% |
Compare RLMD vs Peers
Relmada Therapeutics, Inc. (RLMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RLMD Income Statement
Relmada Therapeutics, Inc. (RLMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'18 | Jun'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 2.63K | 4.87K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -2.63K▲ 0% | -4.87K▼ 85.4% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | 96.92% | -85.38% | 100% | - | - | - | - | - | - |
| Operating Expenses | 6.92M | 12.73M | 15.11M | 60.84M | 125.7M | 161.25M | 103.7M | 83.89M | 1.06M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.98M | 5.7M | 7.25M | 24.87M | 35.08M | 47.93M | 48.9M | 37.72M | 311.9K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 2.94M | 7.03M | 7.86M | 35.97M | 90.62M | 113.32M | 54.81M | 46.18M | 744.56K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 2.35K | 0 | 0 | 0 | 0 | 923 | 0 | 0 | 0 |
| Operating Income | -6.92M▲ 0% | -12.73M▼ 84.0% | -15.11M▼ 18.7% | -60.84M▼ 302.7% | -125.7M▼ 106.6% | -161.25M▼ 28.3% | -103.7M▲ 35.7% | -83.89M▲ 19.1% | -59.1M▲ 29.6% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 4.18% | -84.01% | -18.71% | -302.67% | -106.62% | -28.28% | 35.69% | 19.1% | 29.55% |
| EBITDA | -6.91M | -12.72M | -15.1M | -60.83M | -125.7M | -161.25M | 0 | -83.89M | -59.1M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 3.07% | -84.01% | -18.72% | -302.76% | -106.63% | -28.28% | 100% | - | 29.55% |
| D&A (Non-Cash Add-back) | 2.63K | 4.87K | 4.36K | 3.75K | 1.26K | 2K | 103.7M | 0 | 0 |
| EBIT | -6.92M | -16.56M | -15.11M | -59.34M | -125.7M | -161.25M | -98.79M | -83.89M | -59.1M |
| Net Interest Income | -1.34M | 0 | 104 | 1.4M | 1.2M | 2.66M | 5.15M | 3.53M | 1.4M |
| Interest Income | 0 | -761K | 104 | 1.4M | 1.2M | 2.66M | 5.15M | 3.53M | 1.4M |
| Interest Expense | 1.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -2.04M | -5.7M | 104.11K | 1.38M | -48.32K | 4.21M | 4.91M | 3.91M | 1.72M |
| Pretax Income | -8.96M▲ 0% | -17.32M▼ 93.3% | -15.01M▲ 13.4% | -59.46M▼ 296.2% | -125.75M▼ 111.5% | -157.04M▼ 24.9% | -98.79M▲ 37.1% | -79.98M▲ 19.0% | -57.39M▲ 28.3% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 4.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | -26.5% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -8.96M▲ 0% | -17.32M▼ 93.3% | -15.01M▲ 13.4% | -59.46M▼ 296.2% | -125.75M▼ 111.5% | -157.04M▼ 24.9% | -98.79M▲ 37.1% | -79.98M▲ 19.0% | -57.39M▲ 28.3% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -42.53% | -93.26% | 13.36% | -296.24% | -111.5% | -24.88% | 37.09% | 19.04% | 28.25% |
| Net Income (Continuing) | -8.96M | -17.32M | -15.01M | -59.46M | -125.75M | -157.04M | -98.79M | -79.98M | -57.39M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.86▲ 0% | -2.74▲ 4.2% | -1.63▲ 40.5% | -3.81▼ 133.7% | -7.16▼ 87.9% | -5.30▲ 26.0% | -3.28▲ 38.1% | -2.65▲ 19.2% | -1.45▲ 45.3% |
| EPS Growth % | -37.5% | 4.2% | 40.51% | -133.74% | -87.93% | 25.98% | 38.11% | 19.21% | 45.28% |
| EPS (Basic) | -2.86 | -2.74 | -1.63 | -3.81 | -7.16 | -5.30 | -3.28 | -2.65 | -1.45 |
| Diluted Shares Outstanding | 3.14M | 6.31M | 9.23M | 15.59M | 17.55M | 29.63M | 30.1M | 30.16M | 39.48M |
| Basic Shares Outstanding | 3.14M | 6.31M | 9.23M | 15.59M | 17.55M | 29.63M | 30.1M | 30.16M | 39.48M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
RLMD Balance Sheet
Relmada Therapeutics, Inc. (RLMD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'18 | Jun'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.74M | 9.98M | 116.94M | 118.07M | 223.3M | 152.87M | 97.51M | 45.8M | 93.98M |
| Cash & Short-Term Investments | 2.24M | 9.22M | 116.44M | 117.09M | 211.91M | 148.32M | 96.32M | 44.91M | 93.01M |
| Cash Only | 2.24M | 9.22M | 36.28M | 2.5M | 44.44M | 5.4M | 4.09M | 3.86M | 3.5M |
| Short-Term Investments | 0 | 0 | 80.16M | 114.6M | 167.47M | 142.93M | 92.23M | 41.05M | 89.51M |
| Accounts Receivable | 72.1K | 247.08K | 73.09K | 79.46K | 86.38K | 512.43K | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 426.9K | 459K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 59.31K | 34.4K | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 46 | -10 | 35 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 310.11K | 235.35K | 196K | 112.64K | 28.29K | 34.88K | 43.13K | 21.98K | 19.5K |
| Property, Plant & Equipment | 12.08K | 7.21K | 5.01K | 1.26K | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 273.24K | 203.14K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 24.79K | 25K | 190.99K | 111.38K | 28.29K | 34.88K | 43.13K | 21.98K | 19.5K |
| Total Assets | 3.05M▲ 0% | 10.22M▲ 235.3% | 117.14M▲ 1046.2% | 118.19M▲ 0.9% | 223.33M▲ 89.0% | 152.91M▼ 31.5% | 97.55M▼ 36.2% | 45.82M▼ 53.0% | 94M▲ 105.2% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 7.44% | 235.28% | 1046.17% | 0.9% | 88.96% | -31.53% | -36.2% | -53.03% | 105.17% |
| Total Current Liabilities | 5.9M | 2.61M | 1.46M | 12.6M | 15.06M | 12.47M | 12.19M | 10.29M | 6.43M |
| Accounts Payable | 765.44K | 924.36K | 522.66K | 8.35M | 11.19M | 5.26M | 3.51M | 4.13M | 1.57M |
| Days Payables Outstanding | 106.35K | 69.28K | - | - | - | - | - | - | - |
| Short-Term Debt | 285.17K | 364.2K | 110.25K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 659.5K | 1.32M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.81M | -45 | 250K | 1.8M | 1.64M | 1.02M | 5.68M | 1.15M | 4.86M |
| Current Ratio | 0.46x | 3.83x | 80.21x | 9.37x | 14.83x | 12.26x | 8.00x | 4.45x | 14.62x |
| Quick Ratio | 0.39x | 3.65x | 80.21x | 9.37x | 14.83x | 12.26x | 8.00x | 4.45x | 14.62x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.66M | 0 | 0 | 0 | 0 | 0 | 0 | 4.47K | 1.06M |
| Long-Term Debt | 2.66M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.47K | 1.06M |
| Total Liabilities | 8.56M | 2.61M | 1.46M | 12.6M | 15.06M | 12.47M | 12.19M | 10.3M | 7.49M |
| Total Debt | 2.94M | 364.2K | 110.25K | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | 702.68K | -8.85M | -36.17M | -2.5M | -44.44M | -5.4M | -4.09M | -3.86M | -3.5M |
| Debt / Equity | - | 0.05x | 0.00x | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -5.17x | - | - | - | - | - | - | - | - |
| Total Equity | -5.51M▲ 0% | 7.61M▲ 238.1% | 115.68M▲ 1419.4% | 105.58M▼ 8.7% | 208.26M▲ 97.3% | 140.44M▼ 32.6% | 85.36M▼ 39.2% | 35.52M▼ 58.4% | 86.51M▲ 143.5% |
| Equity Growth % | -477.53% | 238.1% | 1419.42% | -8.73% | 97.25% | -32.57% | -39.22% | -58.38% | 143.55% |
| Book Value per Share | -1.76 | 1.21 | 12.53 | 6.77 | 11.87 | 4.74 | 2.84 | 1.18 | 2.19 |
| Total Shareholders' Equity | -5.51M | 7.61M | 115.68M | 105.58M | 208.26M | 140.44M | 85.36M | 35.52M | 86.51M |
| Common Stock | 3.14K | 9.74K | 14.46K | 16.33K | 27.74K | 30.1K | 30.1K | 30.17K | 73.33K |
| Retained Earnings | -94.34M | -111.66M | -119.86M | -179.32M | -305.07M | -462.11M | -560.9M | -640.88M | -698.27M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RLMD Cash Flow Statement
Relmada Therapeutics, Inc. (RLMD) cash flow — operating, investing & free cash flow history
| Line item | Jun'18 | Jun'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -6M | -10.5M | -12.09K | -27.81M | -91.87M | -103.8M | -51.66M | -51.76M | -45.79M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 7.18% | -74.9% | 99.88% | -229876.85% | -230.38% | -12.98% | 50.23% | -0.19% | 11.53% |
| Net Income | -8.96M | -17.32M | -15.01K | -59.46M | -125.75M | -157.04M | -98.79M | -79.98M | 0 |
| Depreciation & Amortization | 2.63K | 4.87K | 4 | 3.75K | 1.26K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 518K | 1.21M | 2.76K | 20.78M | 40.49M | 44.19M | 43.81M | 30.19M | 0 |
| Deferred Taxes | 708.9K | 3.83M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.03M | 266.76K | 173 | 16.95K | 1.25M | -1.55M | 241.16K | -381.66K | -41.84M |
| Working Capital Changes | 700.06K | 1.51M | -26 | 10.85M | -7.86M | 10.59M | 3.08M | -1.58M | -3.95M |
| Change in Receivables | 224.98K | -169.36K | 0 | 73.09K | 79.46K | -426.06K | 512.43K | 0 | 0 |
| Change in Inventory | 0 | 169.36K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 157.39K | 158.92K | 0 | 7.82M | 2.85M | 421.04K | -1.76M | 624.55K | -2.56M |
| Cash from Investing | -12.39K | 0 | -80.16K | -34.45M | -54.12M | 19.73M | 50.45M | 51.56M | -48.14M |
| Capital Expenditures | -12.39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -80.16K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 6.54M | 17.48M | 126.11K | 28.47M | 187.94M | 45.02M | -98.46K | -40.34K | 93.56M |
| Debt Issued (Net) | 6.54M | -285.17K | 0 | -110.25K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 0 | 1000K | 1000K | 1000K | 0 | 246.75K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 126.11K | 8.06M | 2.63M | 2.29M | -98.46K | -287.09K | -73.02K |
| Net Change in Cash | 528.43K▲ 0% | 6.98M▲ 1220.4% | 6.98K▼ 99.9% | -33.78M▼ 484307.0% | 41.95M▲ 224.2% | -39.05M▼ 193.1% | -1.3M▲ 96.7% | -234.54K▲ 82.0% | -360.49K▼ 53.7% |
| Free Cash Flow | -6.01M▲ 0% | -10.5M▼ 74.5% | -12.09K▲ 99.9% | -27.81M▼ 229876.9% | -91.87M▼ 230.4% | -103.8M▼ 13.0% | -51.66M▲ 50.2% | -51.76M▼ 0.2% | -45.79M▲ 11.5% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 7.7% | -74.54% | 99.88% | -229876.85% | -230.38% | -12.98% | 50.23% | -0.19% | 11.53% |
| FCF per Share | -1.92 | -1.66 | -0.00 | -1.78 | -5.23 | -3.50 | -1.72 | -1.72 | -1.16 |
| FCF Conversion (FCF/Net Income) | 0.67x | 0.61x | 0.00x | 0.47x | 0.73x | 0.66x | 0.52x | 0.65x | 0.80x |
| Interest Paid | 0 | 0 | 0 | 2.42K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RLMD Key Ratios
Relmada Therapeutics, Inc. (RLMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -147.88% | - | -1649.15% | -24.34% | -53.74% | -80.14% | -90.07% | -87.51% | -132.33% | -94.05% |
| Return on Invested Capital (ROIC) | - | - | - | -28.96% | -49.98% | -70.64% | -80.93% | -71.91% | -111.43% | -77.3% |
| Debt / Equity | 0.19x | - | 0.05x | 0.00x | - | - | - | - | - | - |
| Interest Coverage | -13125.45x | -5.17x | - | - | - | - | - | - | - | - |
| FCF Conversion | 1.03x | 0.67x | 0.61x | 0.00x | 0.47x | 0.73x | 0.66x | 0.52x | 0.65x | 0.80x |
RLMD SEC Filings & Documents
Relmada Therapeutics, Inc. (RLMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
RLMD Frequently Asked Questions
Relmada Therapeutics, Inc. (RLMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Relmada Therapeutics, Inc. (RLMD) grew revenue by 0.0% over the past year. Growth has been modest.
Relmada Therapeutics, Inc. (RLMD) reported a net loss of $57.4M for fiscal year 2025.
Dividend & Returns
Relmada Therapeutics, Inc. (RLMD) has a return on equity (ROE) of -94.0%. Negative ROE indicates the company is unprofitable.
Relmada Therapeutics, Inc. (RLMD) had negative free cash flow of $45.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More RLMD
Relmada Therapeutics, Inc. (RLMD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates